HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Consumer Health Industry ‘Relieved’ By Post-Brexit Deal

Executive Summary

UK consumer health industry association PAGB says it is "relieved" a last minute post-Brexit deal has been struck, which will enable its members to continue to supply OTCs to the EU with limited disruption. 

A post-Brexit free trade agreement struck at the eleventh hour before the end of the transition period has been welcomed by UK consumer healthcare association PAGB as a positive outcome for industry.

PAGB said it was “pleased and relieved” that the UK-EU trade and cooperation agreement – which came into force on 1 January 2021 – should allow UK consumer health companies to continue to supply OTC drugs and medical devices to the rest of Europe “with the least possible disruption.”

The deal came just a week before the end of the Brexit transition period and over four years since Britain voted to leave the EU.

Noting that industry had planned extensively for a “range of scenarios” following the EU exit referendum in June 2016, PAGB CEO Michelle Riddalls said consumer healthcare players would be pleased to draw a line under “such a prolonged period of uncertainty.”

Further Clarity Needed

While a broad agreement on trade was welcome, Riddalls pointed out that industry needed more detailed guidance in certain specific areas.

“We still need further clarity about certain elements of the agreement, such as the extent to which some specific Good Manufacturing Practice procedures will be mutually recognized by the EU and the UK,” Riddalls insisted. “It is also important that work continues in the coming months to ensure continuity of medicines supply to Northern Ireland under the terms of the Northern Ireland Protocol.”

Few of the provisions of the more than 1,000-page deal directly affect medicines regulation, other than an annex on the mutual recognition by the UK and the EU of GMP inspections and documents.

According to this annex, the UK and the EU will recognize inspections carried out by one another and accept official GMP documents issued by either side.

However, the document also says that a regulatory agency on either side may “in specific circumstances opt not to accept an official GMP document issued by an authority of the other Party for manufacturing facilities located in the territory of the issuing authority.”

A proposed new body – the Working Group on Medicinal Products – will seek to mediate between the EU and UK on GMP disputes. (Also see "EU-UK Trade Deal Allows For Mutual Recognition Of GMP Inspections" - Pink Sheet, 30 Dec, 2020.)

Northern Ireland Rules Set Out

Turning to Northern Ireland, the UK government has issued guidance for retailers supplying OTC drugs to the country.

Published a day after the PAGB’s statement, the document notes that OTCs can be supplied from Great Britain to Northern Ireland without requiring additional regulatory importation controls – including manufacture and import authorization, batch testing and qualified person (QP) certification done in Northern Ireland or an European Economic Area (EEA) state – until 31 December 2021. (Also see "Stepping Back From The Cliff Edge: UK Industry Welcomes Northern Ireland Brexit Extension" - HBW Insight, 13 Nov, 2020.)

However, from 1 January 2022 Northern Ireland will remain de facto in the EU single market and additional regulatory importation controls will be required, the guidance notes, which will need to be carried out in Northern Ireland or an EEA member state.

OTCs supplied from Great Britain market to Northern Ireland from 2022 will require the following importation controls to be undertaken in Northern Ireland or an EEA Member State, on a per shipment basis:

  • Importation via a Manufacture and Importation Authorization (MIA) holder

  • Batch testing

  • Certification by a QP

The guidance notes that there are alternative supply chain options that will not require importation controls to be performed in Northern Ireland or an EEA Member State. These include:

  • Use of the Common Transit Convention when transporting goods via Great Britain

  • Routing Northern Ireland logistics directly from the EEA

  • Changing the location of batch testing and Qualified Person certification activities

The UK government has already issued specific guidance on how supplying medical devices to Northern Ireland is set to change. (Also see "Self-Care Devices Will Need New UKCA Mark Post-Brexit" - HBW Insight, 3 Sep, 2020.)

In Great Britain, all medical devices will continue to be regulated under the Directive 93/42/EEC on medical devices (MDD), given effect in UK law through the Medical Devices Regulations 2002.

However, medical devices sold in Northern Ireland will be regulated under the new Medical Device Regulation (2017/745) from 26 May 2021, in line with the EU’s implementation timeline.

While Great Britain is introducing its new UKCA certification mark for devices, a CE mark will continue to be needed for devices placed on the Northern Ireland market.

Related Content

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel